--- title: "ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/280470469.md" description: "ProMIS Neurosciences reported a net loss of $39.7 million for FY2025, with a cash balance of $6.1 million. The company raised $75.5 million in February 2026 to fund operations through 2027, following the completion of enrollment in its PRECISE-AD Phase 1b trial with 144 participants. Management anticipates a six-month interim analysis in mid-2026 and top-line data in early 2027. R&D expenses for 2025 were $33.38 million, while general and administrative expenses totaled $6.79 million." datetime: "2026-03-25T12:13:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280470469.md) - [en](https://longbridge.com/en/news/280470469.md) - [zh-HK](https://longbridge.com/zh-HK/news/280470469.md) --- > 支持的语言: [English](https://longbridge.com/en/news/280470469.md) | [繁體中文](https://longbridge.com/zh-HK/news/280470469.md) # ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 ProMIS Neurosciences reported a net loss of $39.7 million for the year ended December 31, 2025 and held $6.1 million in cash at year-end, reflecting continued investment in its PRECISE-AD Phase 1b trial. The company completed enrollment of 144 participants in PRECISE-AD and closed a private placement in February 2026 for $75.5 million upfront proceeds, providing runway through 2027. Management expects a six-month blinded interim analysis in mid‑2026 and top-line 12‑month data in early 2027. **Financial Highlights** - Net loss for year ended December 31, 2025: $39.7 million. - Cash balance as of December 31, 2025: $6.1 million. - Total current assets as of December 31, 2025: $9.18 million. - Total current liabilities as of December 31, 2025: $10.41 million. - Research and development expense for 2025: $33.38 million; general and administrative expense for 2025: $6.79 million. **Business Highlights** - Completed enrollment of PRECISE-AD Phase 1b in December 2025 with 144 participants across three dosing cohorts (5, 10, 20 mg/kg). - PMN310 continues to demonstrate a favorable safety profile with no treatment-related serious adverse events reported to date; DSMB recommended advancement to cohort 3 with no safety concerns. - On track to complete six-month blinded interim assessments in Q2 2026 and to present the blinded interim analysis in early Q3 2026; full dosing expected by year-end 2026 and 12‑month top-line data anticipated in early 2027. - Closed a transformational financing in February 2026 delivering $75.5 million upfront (up to $175 million including warrant exercise proceeds) to fund operations through 2027 and advance development, including a subcutaneous formulation of PMN310 and planning for a potential registrational study. - Advancing preclinical programs: PMN267 (targeting TDP-43 for ALS/FTD) and PMN442 (targeting pathogenic alpha-synuclein for synucleinopathies) have been humanized and are in IND-enabling preparation. Original SEC Filing: ProMIS Neurosciences Inc. \[ PMN \] - 8-K - Mar. 25, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### 相关股票 - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [Minerva Neurosciences (NERV.US)](https://longbridge.com/zh-CN/quote/NERV.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [ProMIS Neurosciences (PMN.US)](https://longbridge.com/zh-CN/quote/PMN.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) ## 相关资讯与研究 - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-CN/news/281024362.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-CN/news/281015927.md) - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-CN/news/281025352.md) - [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/zh-CN/news/280971278.md) - [Tozorakimab shows significant benefit in two major COPD trials](https://longbridge.com/zh-CN/news/280991938.md)